(OVERALL) The University of Michigan Comprehensive Cancer Center (UMCCC) has a distinguished history of scientific excellence, collaboration, and impact. Its mission is to reduce cancer burden and improve cancer outcomes through research, innovation, transdisciplinary collaboration, education, and outreach and engagement. The vision of the UMCCC is that through its focus on team science and research excellence, the UMCCC will be a national leader in prevention, early diagnosis, optimal treatment, and survivorship care for those at risk of or affected by cancer. Founded in 1986 as the matrix cancer center of the University of Michigan (U-M), the UMCCC first received National Cancer Institute (NCI) designation in 1988, and it has been a comprehensive cancer center since 1991. With strong support from the U-M leadership team and the UMCCC community, Eric Fearon, MD, PhD, was appointed as the third UMCCC Director in September 2016. Dr. Fearon has held multiple leadership roles in UMCCC throughout the past two decades, including Deputy Director, AD for Basic Sciences, and Program Co-Leader for Cancer Genetics. The Center provides an organizational framework to promote transdisciplinary cancer research through the development of well-funded basic, translational, clinical, and prevention programs and the development of shared resources. The Cancer Center?s seven research programs includes four basic programs ? Cancer Biology, Cancer Genetics, Cancer Hematopoiesis and Immunology and Developmental Therapeutics; the Translational and Clinical Research Program; and two cancer control and population sciences programs ? Health Behavior and Outcomes and Cancer Epidemiology and Prevention. UMCCC supports 11 Shared Resources and two developing Shared Resources: Biostatistics, Analytics and Bioinformatics; Cell and Tissue Imaging; Experimental Irradiation; Flow Cytometry; Health Communications; Immune Monitoring; Pharmacokinetics; Preclinical Imaging and Computational Analysis; Structure and Drug Screening; Tissue and Molecular Pathology; Transgenic Animal Models; Proteomics (developing); and Single Cell Analysis (developing). The UMCCC has 287 members representing 50 departments and eight schools and colleges across the University of Michigan. The UMCCC was ranked in the top 10 of NCI-funded academic institutions in 2016 and UMCCC members have annual direct funding of over $100 million. The scientific impact of UMCCC research is reflected through the roughly 4400 UMCCC member publications during the 2012-2016 period, including 15% of UMCCC manuscripts published in journals with impact factor >10, and the strong portfolio of cancer-focused grants held by our members. Fostering transdisciplinary collaboration is a key tenet of UMCCC, evidenced by a high degree of intra- (23.7%) and inter-programmatic publications (31.6%). The Medical School has made substantial commitments to UMCCC through space, financial support, and the recognition of cancer programs as a top priority for the institution.

Public Health Relevance

(OVERALL) The University of Michigan Comprehensive Cancer Center (UMCCC) is committed to reducing cancer burden and improving cancer outcomes through research, innovation, transdisciplinary collaboration, education, and outreach. The UMCCC vision is that through its focus on team science and excellence, the UMCCC will be a national leader in prevention, early diagnosis, optimal treatment, and survivorship care for those at risk of or affected by cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Internal Medicine/Medicine
Schools of Medicine
Ann Arbor
United States
Zip Code
Ma, Vincent T; Boonstra, Philip S; Menghrajani, Kamal et al. (2018) Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clin Lymphoma Myeloma Leuk 18:e201-e210
Collins, Dalis; Fry, Christopher; Moore, Bethany B et al. (2018) Phagocytosis by Fibrocytes as a Mechanism to Decrease Bacterial Burden and Increase Survival in Sepsis. Shock :
Moody, Rebecca Reed; Lo, Miao-Chia; Meagher, Jennifer L et al. (2018) Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem 293:2125-2136
Hawkins, Allegra G; Basrur, Venkatesha; da Veiga Leprevost, Felipe et al. (2018) The Ewing Sarcoma Secretome and Its Response to Activation of Wnt/beta-catenin Signaling. Mol Cell Proteomics 17:901-912
Cooper, Gregory S; Markowitz, Sanford D; Chen, Zhengyi et al. (2018) Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing. Dig Dis Sci 63:1449-1453
Wang, Xuexiang; Dande, Ranadheer R; Yu, Hao et al. (2018) TRPC5 Does Not Cause or Aggravate Glomerular Disease. J Am Soc Nephrol 29:409-415
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Schofield, Heather K; Zeller, Jörg; Espinoza, Carlos et al. (2018) Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight 3:
Djuric, Zora; Bassis, Christine M; Plegue, Melissa A et al. (2018) Colonic Mucosal Bacteria Are Associated with Inter-Individual Variability in Serum Carotenoid Concentrations. J Acad Nutr Diet 118:606-616.e3

Showing the most recent 10 out of 1493 publications